Technical Analysis for SYRS - Syros Pharmaceuticals, Inc.
Grade | Last Price | % Change | Price Change |
---|---|---|---|
F | 8.89 | -2.95% | -0.27 |
Earnings due: Mar 4
*** please verify all earnings dates ***ADX | Long Term | Intermediate Term | Short Term |
---|---|---|---|
Weak or Absent | Down | Down | Down |
Historical SYRS trend table... |
Date | Alert Name | Type | % Chg |
---|---|---|---|
Narrow Range Bar | Range Contraction | -2.95% | |
NR7 | Range Contraction | -2.95% | |
Inside Day | Range Contraction | -2.95% | |
Wide Bands | Range Expansion | -2.95% | |
Oversold Stochastic | Weakness | -2.95% | |
Stochastic Buy Signal | Bullish | -5.93% | |
Lower Bollinger Band Walk | Weakness | -5.93% | |
Wide Bands | Range Expansion | -5.93% | |
Oversold Stochastic | Weakness | -5.93% | |
Lower Bollinger Band Walk | Weakness | 5.83% |
Recent Intraday Alerts -- Get these alerts pushed to you via our Mobile App
Alert | Time | |
---|---|---|
60 Minute Opening Range Breakdown | about 22 hours ago | |
Down 2 % | about 22 hours ago | |
Down 1% | about 24 hours ago | |
Up 1% | about 24 hours ago | |
60 Minute Opening Range Breakout | 2 days ago |
Get a Trading Sidekick!
- Earnings date: 03/04/2021
Syros Pharmaceuticals, Inc. Description
Syros Pharmaceuticals, Inc., a biopharmaceutical company, focuses on developing medicines that control genes to transform the lives of patients with cancer, immune-mediated diseases, and other diseases. The company's gene control platform identifies gene control targets linked to genomically defined patient populations and drugging gene control targets; identifies potential new drug targets across a range of diseases; provides lens for diagnosing and segmenting patients, including those with complex/multi-factorial diseases; and allows users to advance a wave of medicines with the potential to influence multiple drivers of disease through a single target. Its pipeline includes SY-1425, a selective RARa agonist for genomically defined subsets of patients with relapsed or refractory acute myeloid leukemia and relapsed high-risk myelodysplastic syndrome; and SY-1365, a selective CDK7 inhibitor for acute leukemia. Syros Pharmaceuticals, Inc. was formerly known as LS22, Inc. Syros Pharmaceuticals, Inc. was founded in 2011 and is based in Cambridge, Massachusetts.
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Biopharmaceutical Cancer Diseases Disease Medication Acute Myeloid Leukemia Leukemia Myelodysplastic Syndrome Immune Mediated Diseases Acute Leukemia Refractory Acute Myeloid Leukemia
Indicator | Bull Case | Neutral / Hold | Bear Case |
---|---|---|---|
50 DMA | |||
200 DMA | |||
ADX Trend | |||
Oversold / Overbought | |||
Relative Strength |
Indicator | Value |
---|---|
52 Week High | 15.65 |
52 Week Low | 4.26 |
Average Volume | 799,941 |
200-Day Moving Average | 10.39 |
50-Day Moving Average | 11.61 |
20-Day Moving Average | 10.94 |
10-Day Moving Average | 9.86 |
Average True Range | 1.04 |
ADX | 18.91 |
+DI | 17.26 |
-DI | 27.99 |
Chandelier Exit (Long, 3 ATRs ) | 10.34 |
Chandelier Exit (Short, 3 ATRs ) | 11.34 |
Upper Bollinger Band | 13.60 |
Lower Bollinger Band | 8.28 |
Percent B (%b) | 0.17 |
BandWidth | 48.65 |
MACD Line | -0.72 |
MACD Signal Line | -0.45 |
MACD Histogram | -0.2696 |
Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
---|---|---|---|---|---|
Resistance 4 (R4) | 9.86 | ||||
Resistance 3 (R3) | 9.94 | 9.78 | 9.74 | ||
Resistance 2 (R2) | 9.78 | 9.60 | 9.74 | 9.71 | |
Resistance 1 (R1) | 9.47 | 9.49 | 9.39 | 9.39 | 9.67 |
Pivot Point | 9.32 | 9.32 | 9.28 | 9.28 | 9.32 |
Support 1 (S1) | 9.00 | 9.14 | 8.93 | 8.93 | 8.65 |
Support 2 (S2) | 8.85 | 9.03 | 8.81 | 8.61 | |
Support 3 (S3) | 8.54 | 8.85 | 8.58 | ||
Support 4 (S4) | 8.46 |